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Abstract
Background: Despite the multitude of public health and community harms associated with crack cocaine use,
little is known about factors associated with smoking crack in public and related risks such as rushed public
crack smoking.
Methods: Data were derived from two prospective cohort studies of people who use illicit drugs in Vancouver,
Canada between 2010 and 2014. Multivariable generalized estimating equations were used to identify the
prevalence and correlates of public crack smoking and rushed public crack smoking.
Results: In total, 1085 participants who had smoked crack in the prior six months were eligible for the analysis, of
which 379 (34.9 %) reported always or usually smoking crack in public in the previous six months at some point
during the study period. Factors positively and independently associated with public crack smoking included
public injection drug use (adjusted odds ratio [AOR]: 5.42, 95 % confidence interval [CI]: 3.76-7.82), homelessness
(AOR: 3.48, 95 % CI: 2.77-4.36), at least daily crack use (AOR: 2.69, 95 % CI: 2.19-3.31), crack pipe sharing (AOR: 1.98,
95 % CI: 1.60-2.46), drug dealing (AOR: 1.59, 95 % CI: 1.30-1.94), recent incarceration (AOR: 1.47, 95 % CI: 1.09-1.98),
noticing police presence when buying or using drugs (AOR: 1.30, 95 % CI: 1.06-1.60), and younger age (AOR: 1.03,
95 % CI: 1.01-1.04). Rushed public crack smoking, which was reported by 216 (28.8 %) of 751 participants who had
smoked crack in public at least once during the study period, was positively and independently associated with
homelessness (AOR: 2.61, 95 % CI: 1.96-3.49), at least daily crack use (AOR: 1.48, 95 % CI: 1.11-1.98), crack pipe
sharing (AOR: 1.44, 95 % CI: 1.10-1.89), drug dealing (AOR: 1.39, 95 % CI: 1.04-1.86), and younger age (AOR: 1.02,
95 % CI: 1.01-1.04).
Conclusions: A high prevalence of public crack smoking and rushed public crack smoking was observed in
this setting. These findings point to the need for implementing and evaluating evidence-based public health
interventions, such as supervised inhalation facilities, to reduce the risks and harms associated with smoking crack
in public.
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Background
In recent years, increases in crack cocaine use in many
North American settings have contributed to a “neglected
epidemic” in which crack cocaine has remained among
the most prevalent and easily obtainable illicit drugs
[1–3]. National population-level surveys estimate that
past-year crack cocaine use is prevalent in approximately
1.1 % and 0.3 % of the general adult populations in Canada
and the United States, respectively [4, 5]. A recent multi-
criteria decision analysis performed by the Independent
Scientific Committee on Drugs found that crack cocaine
(herein referred to as “crack”) is among the top three illicit
drugs that are most harmful to individual users and to
others, due to its potential for causing substantial physical,
psychological, and social harms [6]. Specifically, individ-
uals who use crack have been found to have elevated risk
of HIV, hepatitis C virus (HCV), tuberculosis, herpes zos-
ter, and other infectious pathogens secondary to sores,
burns, or cuts, either from shared crack pipes or from in-
creased prevalence of sexual risk behaviors [7–14]. Add-
itionally, crack use has been found to be associated with
polysubstance use, comorbid mental illness, incarceration,
and other health and social-structural problems, yet re-
search indicates that individuals who use crack may be
less likely to access health and social services [3, 15–17].
Crack is often smoked in public settings, which may
contribute to public health risks such as hazardous
debris from crack smoking paraphernalia potentially
contaminated with infectious pathogens (e.g., from glass
crack pipes), as well as crack-related street disorder such
as public intoxication, dealing drugs in public, or related
violence [18–20]. To date, much of the literature on
public drug use has focused on the use of injection
drugs in public and associated risks. Specifically, public
injecting has been found to be associated with greater
odds of injection-related risk behaviours (e.g., sharing
used injection equipment, not cooking or filtering drugs
prior to injecting), HIV and HCV transmission, and poor
health and social status (e.g., more severe drug depend-
ency, social isolation, and unstable lifestyles) [21–23].
However, little is known about risks associated with the
use of non-injection drugs in public settings—particularly
crack.
Furthermore, there is a dearth of research on factors
associated with the use of non-injection drugs while
rushed. Here again, much of the literature has concen-
trated on rushed injection drug use, which is often
prompted by fear of police arrest or street violence, and
which frequently involves risky injection behaviors (e.g.,
jabbing at veins, not testing the strength of drugs before
injecting, re-using injecting equipment) that may lead to
vein trauma, abscesses, overdose, bacterial infections, or
infectious disease transmission [24–26]. The risks asso-
ciated with rushed crack smoking are not well described,
apart from one study which found a high prevalence of
burns and inhaled metallic crack pipe filter screens
among individuals who reported rushed crack smoking
[27]. Therefore, this study sought to investigate the
prevalence and correlates of public crack smoking and
rushed public crack smoking among participants of two
prospective cohorts of people who use illicit drugs in
Vancouver, Canada.
Methods
Data for these analyses were derived from two prospective
observational cohorts in Vancouver, Canada: the AIDS
Care Cohort to evaluate Exposure to Survival Services
(ACCESS) of HIV-seropositive illicit drug users and the
Vancouver Injection Drug Users Study (VIDUS) of
HIV-seronegative injection drug users. These cohorts
have previously been described in detail [28, 29]. In short,
since 1996, more than 2000 individuals have been re-
cruited into these cohorts through snowball sampling and
street outreach methods in Vancouver’s Downtown
Eastside, a post-industrial neighbourhood with an estab-
lished drug market and widespread illicit drug use, pov-
erty, poor housing conditions, and infectious diseases
such as HIV and HCV [30].
Participants are eligible for VIDUS if they are HIV-
seronegative, over 18 years of age, and have injected an
illicit drug in the month prior to the baseline interview.
Participants are eligible for ACCESS if they are HIV-
seropositive, over the age of 18, and have used an illicit
drug other than or in addition to cannabis within the
month prior to the baseline interview. As these two co-
horts were originally one single cohort until they were split
into the two present cohorts in 2005, the two cohorts
employ harmonized data collection and follow-up
procedures to allow for combined analyses of the HIV-
seronegative and HIV-seropositive study participants. Spe-
cifically, at baseline and semi-annually, participants answer
an interviewer-administered questionnaire, which elicits
data on demographic characteristics, drug-using behav-
iours and related exposures; provide blood samples for
HIV (for VIDUS participants only) and HCV serologic
analyses; and are referred as necessary to medical care and
drug and alcohol treatment. All participants provide
written informed consent and receive a $30 stipend at the
end of each study visit. These studies have received annual
ethics approval from the University of British Columbia
and Providence Health Care Research Ethics Board.
The present analyses were restricted to interviews that
were conducted between December 1, 2010 to May 31,
2014. Participants were eligible for this analysis if they
reported smoking crack at least once in the six-month
period prior to their interview, and if they had a history
of ever injecting any drug at the time of interview. The
main outcome measure of interest was smoking crack in
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public (always or usually vs. sometimes, occasionally or
never) [31]. The self-reported demographic, behavioural,
social and structural explanatory characteristics consid-
ered in the analyses were: age (per one-year decrease);
gender (female vs. male); HIV serostatus (positive vs. nega-
tive); homelessness (yes vs. no); drug dealing (yes vs. no);
sex work (yes vs. no); crack smoking (≥ daily vs. < daily);
sharing a crack pipe (yes vs. no); binge non-injection drug
use (yes vs. no); heroin injection (≥ daily vs. < daily);
cocaine injection (≥ daily vs. < daily); crystal methampheta-
mine injection (≥ daily vs. < daily); public injection drug
use (always or usually vs. sometimes, occasionally or
never); noticing police presence when buying or using
drugs (yes vs. no); being stopped, searched or detained
without arrest by police (yes vs. no); recent incarceration
(yes vs. no); enrolment in drug addiction treatment,
excluding methadone (yes vs. no); and being a victim of
violence (yes vs. no). All variables referred to activities or
events in the six months prior to the participant’s inter-
view, unless otherwise indicated. As in previous studies,
binge non-injection drug use was defined as any period of
time within the previous six months from the time of inter-
view during which any drugs were used more frequently
than usual [32].
First, we compared those who did and did not smoke
crack in public at baseline using Pearson’s Chi-squared
test for dichotomous variables and the Wilcoxon rank
sum test for continuous variables. Next, since analyses
of factors potentially associated with public crack smok-
ing included serial measures for each subject, we used
generalized estimating equations (GEE) with logit link
function and exchangeable working correlation structure
to account for correlations between repeated measure-
ments. Bivariable GEE analyses were conducted to ob-
tain unadjusted odds ratios and p-values for factors
associated with public crack smoking. Using an a priori-
defined statistical protocol based on examination of the
quasi-likelihood under the independence model criterion
(QIC) value, a preliminary multivariable model was built
using all variables that were significantly associated with the
outcome at the p < 0.10 in the bivariable analyses. Next,
each variable with the highest p-value was removed sequen-
tially. The final model included the set of variables associ-
ated with the lowest QIC, and was assessed with variance
inflation factors to ensure the absence of multicollinearity.
As a secondary analysis, among participants who re-
ported any public crack smoking (i.e., always, usually,
sometimes, or occasionally), bivariable and multivariable
GEE analyses were conducted to determine factors asso-
ciated with rushed public crack smoking, using the same
procedures detailed above. All p-values were two sided.
A significant association was defined as p < 0.05. All stat-
istical analyses were performed using the SAS software
version 9.4 (SAS, Cary, NC).
Results
Of the 1085 participants eligible for the present analysis,
400 (36.9 %) were female. The median age at the first
study visit was 46 (interquartile range: 40—52) years.
Participants in this sample contributed to a total of 5126
observations during the study period. Table 1 shows the
baseline sample characteristics. At the first study visit,
244 (22.5 %) participants reported “always” or “usually”
smoking crack in public in the previous six months.
During the 42-month study period, 379 (34.9 %) partici-
pants reported “always” or “usually” smoking crack in
public at least once.
Table 2 presents the results of the bivariable and multi-
variable GEE analyses. In multivariable GEE analyses, fac-
tors that remained positively and independently associated
with public crack smoking included: public injection drug
use (adjusted odds ratio [AOR]: 5.42, 95 % confidence
interval [CI]: 3.76-7.82), homelessness (AOR: 3.48, 95 %
CI: 2.77-4.36), at least daily crack use (AOR: 2.69, 95 % CI:
2.19-3.31), crack pipe sharing (AOR: 1.98, 95 % CI:
1.60-2.46), drug dealing (AOR: 1.59, 95 % CI: 1.30-1.94),
recent incarceration (AOR: 1.47, 95 % CI: 1.09-1.98), no-
ticing police presence (AOR: 1.30, 95 % CI: 1.06-1.60), and
younger age (AOR: 1.03, 95 % CI: 1.01-1.04).
Of the 751 participants who smoked crack in public at
least once, rushed public crack smoking was reported by
216 (28.8 %) participants at least once during the study
period. Table 3 shows the factors positively and inde-
pendently associated with rushed public crack smoking
in multivariable GEE analyses, which included: home-
lessness (AOR: 2.61, 95 % CI: 1.96-3.49), at least daily
crack use (AOR: 1.48, 95 % CI: 1.11-1.98), crack pipe
sharing (AOR: 1.44, 95 % CI: 1.10-1.89), drug dealing
(AOR: 1.39, 95 % CI: 1.04-1.86), and younger age (AOR:
1.02, 95 % CI: 1.01-1.04).
Discussion
In this study, more than one-third of participants who
had smoked crack reported “always or usually” smoking
crack in public at some point during the study period.
Of the participants who had smoked crack in public at
least once, 28.8 % reported rushed public crack smoking.
This study found that individuals who were homeless
had elevated odds of public crack use and rushed public
crack use compared to individuals who were not home-
less, which is consistent with other literature that has
found that homelessness is one of the strongest predic-
tors of using injection drugs in public [22, 33–35].
Among individuals who use crack in particular, rates of
homelessness have been found to be disproportionately
higher than individuals who use other illicit drugs [2].
Therefore, one way to reduce risky public crack use may
involve addressing barriers to securing stable housing
among this population, such as increasing accessibility
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Table 1 Baseline characteristics of VIDUS and ACCESS participants who smoked crack in Vancouver, Canada, stratified by public
crack smoking (n = 1085)
Characteristic Smoked crack in publica
244 (22.5 %)
n (%)
Did not smoke crack in publicb
841 (77.5 %)
n (%)
Odds ratio (95 % CI) p - value
Age
Median years 42.1 47.2 1.05 (1.04, 1.08) <0.001
(IQR) (36.1 – 47.0) (40.7 – 52.5)
Gender
Female 93 (38.1) 307 (36.5) 1.07 (0.80, 1.44) 0.646
Male 151 (61.9) 534 (63.5)
HIV serostatus
Positive 90 (36.9) 406 (48.3) 0.63 (0.47, 0.84) 0.002
Negative 154 (63.1) 435 (51.7)
Homelessnessc,d
Yes 115 (47.1) 109 (13.0) 6.02 (4.36, 8.31) <0.001
No 128 (52.5) 730 (86.8)
Drug Dealingc
Yes 106 (43.4) 156 (18.5) 3.37 (2.48, 4.59) <0.001
No 138 (56.6) 685 (81.5)
Sex workc, a
Yes 40 (16.4) 95 (11.3) 1.56 (1.05, 2.33) 0.029
No 201 (82.4) 745 (88.6)
Crack smokingc,d
≥ Daily 136 (55.7) 254 (30.2) 2.90 (2.16, 3.89) <0.001
< Daily 108 (44.3) 585 (69.6)
Shared crack pipec
Yes 143 (58.6) 384 (45.7) 1.68 (1.26, 2.25) <0.001
No 101 (41.4) 457 (54.3)
Binge non-injection drug usec
Yes 99 (40.6) 341 (40.5) 1.01 (0.75, 1.34) 0.994
No 145 (59.4) 500 (59.5)
Heroin injectionc
≥ Daily 78 (32.0) 113 (13.4) 3.03 (2.17, 4.23) <0.001
< Daily 166 (68.0) 728 (86.6)
Cocaine injectionc,d
≥ Daily 28 (11.5) 43 (5.1) 2.40 (1.46, 3.95) <0.001
< Daily 216 (88.5) 796 (94.6)
Crystal meth injectionc
≥ Daily 10 (4.1) 27 (3.2) 1.29 (0.61, 2.70) 0.501
< Daily 234 (95.9) 814 (96.8)
Public injection drug usec,d
Always or usually 59 (24.2) 19 (2.3) 13.80 (8.04, 23.72) <0.001
Sometimes, occasionally or never 184 (75.4) 818 (97.3)
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to supportive housing and housing support staff who
may assist with issues such as social assistance and
tenancy rights [22].
In this study, individuals who smoked crack in public
had a five-fold increased odds of also having injected
drugs in public, which is concerning given the added risk
of infection and disease transmission associated with
public injection drug use [21–23]. Daily crack use and
crack pipe sharing were also significantly associated with
public crack use and rushed public crack use. These
findings suggest that individuals who smoke crack in
public may at increased risk of transmitting HIV, HCV
and other infectious pathogens [7–15]. The finding that
rushed public crack use was significantly associated with
crack pipe sharing is especially concerning, given that
rushed drug use is often characterized by inattention to
hygiene and harm reduction practices, which may fur-
ther exacerbate the risk of infectious disease transmis-
sion [24–26]. Therefore, greater efforts are needed to
reduce barriers to distributing sterile crack pipes to re-
duce risky pipe sharing, especially given literature sug-
gesting that crack pipe sharing is significantly associated
with difficulty obtaining new pipes [31, 36].
Individuals who used crack in public in the present
study demonstrated higher odds of recent incarceration
and noticing police presence. These findings echo other
research that has found that individuals who use drugs
in public are often involved in the criminal justice sys-
tem [23, 33, 34, 37] and are often fearful of, hassled, or
shamed by police, which may perpetuate drug use in
riskier environments perceived to be less exposed to po-
lice (e.g., alleys, dumpsters, hidden doorways) [26, 35].
However, such hidden environments often pose high risk
for fatal overdose due to individuals being out of sight
from passersby, injury or infection due to hazardous
litter that is frequently found in such areas (e.g., used
needles or crack pipes), or lack of access to sterile sup-
plies in such settings [21, 26].
Individuals who reported public crack use and rushed
public crack use were also more likely to have recently
engaged in drug dealing. A limited body of literature has
found that public crack use is associated with drug deal-
ing [37], and that crack users are more likely than non-
crack users to report illegal activities such as drug
dealing as a method of income generation [15]. One po-
tential explanation is that drug dealing and public crack
use both occur at street level, where individuals may
spend a large portion of their time [18]. Therefore,
street-level harm reduction interventions such as utiliz-
ing street outreach programs to distribute sterile drug
use equipment and provide safer drug use education
may be beneficial for this population [38, 39]. Addition-
ally, improving access to low-threshold employment op-
portunities for this population may reduce the need for
individuals to rely on street-level income-generating
activities, and in turn potentially reduce drug use and
related harms [40].
Collectively, these findings suggest the potential for
evidence-based public health interventions to reduce the
harms associated with public crack use and rushed
Table 1 Baseline characteristics of VIDUS and ACCESS participants who smoked crack in Vancouver, Canada, stratified by public
crack smoking (n = 1085) (Continued)
Noticed police presencec,d
Yes 175 (71.7) 536 (63.7) 1.47 (1.07, 2.02) 0.016
No 67 (27.5) 302 (35.9)
Stopped, searched or detained without arrest by policec,d
Yes 57 (23.4) 90 (10.7) 2.62 (1.81, 3.80) <0.001
No 181 (74.2) 750 (89.2)
Incarcerationc, a
Yes 43 (17.6) 55 (6.5) 3.13 (2.04, 4.81) <0.001
No 196 (80.3) 785 (93.3)
Drug addiction treatment (excluding methadone)c,d
Yes 148 (60.7) 525 (62.4) 0.96 (0.71, 1.28) 0.766
No 92 (37.7) 312 (37.1)
Victim of violencec,d
Yes 39 (16.0) 128 (15.2) 1.08 (0.73, 1.59) 0.710
No 200 (82.0) 707 (84.1)
aDefined as “always” or “usually” smoking crack in public in the previous six months
bDefined as “sometimes,” “occasionally” or “never” smoking crack in public in the previous six months
cDenotes activities/events in the previous six months
dCounts may not add up to column totals due to missing responses
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public crack use. While the evidence in support of
supervised injection facilities is now well-established
[41–45], the implementation of supervised inhalation
rooms has been slow to follow suit, despite the over-
whelming benefit that such facilities may offer in terms
of providing a safe, non-rushed environment; sterile
equipment to prevent disease transmission; direct access
to health and social services for this hard-to-engage
population prone to fatal overdose, infection, and other
complex health concerns; immediate support for addic-
tion treatment and counselling; reducing public drug use
and related disorder; and affording considerable cost
Table 2 Bivariable and multivariable GEE analyses of factors associated with public crack smoking in the previous six months among
VIDUS and ACCESS participants who smoked crack in Vancouver, Canada (n = 1085)
Unadjusted Adjusted
Characteristic Odds ratio (95 % CI) p-value Odds ratio (95 % CI) p-value
Age
(per one-year decrease) 1.06 (1.05 – 1.08) <0.001 1.03 (1.01 – 1.04) <0.001
Gender
(female vs. male) 1.09 (0.86 – 1.39) 0.465
HIV serostatus
(positive vs. negative) 0.71 (0.56 – 0.91) 0.006
Homelessnessa
(yes vs. no) 4.55 (3.71 – 5.59) <0.001 3.48 (2.77 – 4.36) <0.001
Drug dealinga
(yes vs. no) 2.76 (2.30 – 3.32) <0.001 1.59 (1.30 – 1.94) <0.001
Sex worka
(yes vs. no) 1.94 (1.48 – 2.54) <0.001
Crack smokinga
(≥ daily vs. < daily) 3.11 (2.59 – 3.74) <0.001 2.69 (2.19 – 3.31) <0.001
Shared crack pipea
(yes vs. no) 2.78 (2.31 – 3.34) <0.001 1.98 (1.60 – 2.46) <0.001
Binge non-injection drug usea
(yes vs. no) 1.44 (1.24 – 1.67) <0.001
Heroin injectiona
(≥ daily vs. < daily) 2.21 (1.72 – 2.84) <0.001
Cocaine injectiona
(≥ daily vs. < daily) 1.48 (1.09 – 1.99) 0.011
Crystal meth injectiona
(≥ daily vs. < daily) 0.89 (0.57 – 1.40) 0.626
Public injection drug usea
(Always or usually vs. sometimes, occasionally or never) 7.46 (5.42 – 10.28) <0.001 5.42 (3.76 – 7.82) <0.001
Noticed police presencea
(yes vs. no) 1.67 (1.42 – 1.97) <0.001 1.30 (1.06 – 1.60) 0.013
Stopped, searched or detained without arrest by policea
(yes vs. no) 1.98 (1.61 – 2.44) <0.001
Incarcerationa
(yes vs. no) 2.36 (1.79 – 3.11) <0.001 1.47 (1.09 – 1.98) 0.011
Drug addiction treatment (excluding methadone)a
(yes vs. no) 0.95 (0.78 – 1.16) 0.622
Victim of violencea
(yes vs. no) 1.52 (1.22 – 1.88) <0.001
aDenotes activities/events in the previous six months
Voon et al. BMC Public Health  (2016) 16:476 Page 6 of 9
savings for health care systems [15, 46–49]. Notably, the
implementation of supervised inhalation rooms need not
be separate from supervised injection facilities; in fact,
the delivery of both supervised injection and inhalation
(or other non-injection drug use) in a single ‘safe drug
use facility’ may be a more feasible and accessible ap-
proach for this population. Although individuals who
use crack have previously reported high rates of willing-
ness to use supervised inhalation rooms [27, 37, 50],
policy barriers continue to impede the implementation
of these potentially life-saving facilities [51].
In addition to the social and structural interventions
described above, more immediate public health interven-
tions to reduce the harms associated with public crack
use may include distributing sterile crack smoking
equipment and installing safe disposal containers for
used crack equipment in public places [21, 35, 52, 53].
Notably, these interventions hold benefit for users of
other non-injection drugs (e.g., methamphetamine,
heroin), and may even play a crucial role in supporting
the transition from injection drug use to less risky forms
of non-injection drug use [46, 52, 54]. Furthermore,
more research is needed on effective treatments for
stimulant dependence, as currently no single approach
has yet shown consistent evidence for effectively redu-
cing or sustaining abstinence for stimulant use [55–59].
This study has several limitations. First, our study re-
lied on self-reported data that is susceptible to socially
desirable reporting and recall bias. Second, because the
study sample was not randomly selected, these results
may not be generalizable to other populations. Related
to this, as there is a lack of research on crack cocaine
use in general population samples—including estimates
of co-occurring crack smoking and injection drug use
Table 3 Bivariable and multivariable GEE analyses of factors associated with rushed public crack smoking in the previous six months
among VIDUS and ACCESS participants in Vancouver, Canada who smoked crack in public at least once (n = 751)
Unadjusted Adjusted
Characteristic Odds ratio (95 % CI) p-value Odds ratio (95 % CI) p-value
Age
(per one-year decrease) 1.04 (1.02 – 1.06) <0.001 1.02 (1.01 – 1.04) 0.019
Gender
(female vs. male) 1.35 (1.01 – 1.80) 0.045 1.23 (0.90 – 1.69) 0.185
Homelessnessa
(yes vs. no) 2.86 (2.18 – 3.76) <0.001 2.61 (1.96 – 3.49) <0.001
Drug dealinga
(yes vs. no) 1.86 (1.41 – 2.44) <0.001 1.39 (1.04 – 1.86) 0.026
Sex worka
(yes vs. no) 1.25 (0.86 – 1.81) 0.241
Crack smokinga
(≥ daily vs. < daily) 1.71 (1.30 – 2.24) <0.001 1.48 (1.11 – 1.98) 0.007
Shared crack pipea
(yes vs. no) 1.65 (1.28 – 2.14) <0.001 1.44 (1.10 – 1.89) 0.008
Binge non-injection drug usea
(yes vs. no) 1.28 (1.00 – 1.64) 0.051
Noticed police presencea
(yes vs. no) 1.19 (0.88 – 1.60) 0.250
Stopped, searched or detained without arrest by policea
(yes vs. no) 1.68 (1.22 – 2.31) 0.001
Incarcerationa
(yes vs. no) 1.90 (1.30 – 2.78) <0.001 1.43 (0.95 – 2.15) 0.084
Drug addiction treatment (excluding methadone)a
(yes vs. no) 0.97 (0.73 – 1.28) 0.828
Victim of violencea
(yes vs. no) 1.36 (0.96 – 1.92) 0.088
aDenotes activities/events in the previous six months
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and estimates of public crack smoking—it is difficult to
compare these findings to other populations. Therefore,
more research on crack smoking in general population
samples is needed. Finally, as in all observational studies
of this kind, the associations between the explanatory
variables and the outcomes assessed may have been
under the influence of unmeasured confounding, al-
though we sought to address this bias with multivariable
adjustment involving key potential correlates of public
crack smoking.
Conclusions
In summary, a high prevalence of public crack smoking
and rushed public crack smoking was observed in this
study. These behaviours were associated with an array of
factors highlighting the vulnerability of this population,
including homelessness, younger age, public injection
drug use, daily crack use, crack pipe sharing, exposure
to law enforcement, and involvement in drug dealing.
These findings point to the need for implementing and
evaluating evidence-based social, structural, and public
health interventions, such as supervised inhalation
facilities, to reduce the risks and harms associated with
smoking crack in public.
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